Open AccessUse of PD ‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report
Author(s) -
Xu Li,
Tao Ningning,
Liang Bin,
Li Daowei,
Li Huaichen,
Su Lili
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14290
Subject(s) - medicine , immunotherapy , sarcomatoid carcinoma , targeted therapy , stage (stratigraphy) , carcinoma , pd l1 , metastasis , lung cancer , oncology , lung , cancer research , cancer , paleontology , biology
Pulmonary sarcomatoid carcinoma (PSC), characterized by poor differentiation, aggressive progression, and early metastasis, is a rare type of non‐small cell lung carcinoma (NSCLC), which shows a low response rate to conventional antitumor therapies and has a poor prognosis. With the achievements in gene sequencing, targeted therapy, and immunotherapy, several new approaches have recently been explored in PSC treatment. A small case series of PSC patients were found to have programmed death‐ligand 1 (PD‐L1) overexpression, a prerequisite for PD‐1 inhibiting therapy, which made immunotherapy possible. However, anti‐PD‐1 treatment for PSCs was still at a preliminary stage. Here, we report the successful outcome of tislelizumab monotherapy in a patient with advanced PSC with pleural invasion, thus providing a novel promising approach for PSC patients with PD‐L1 overexpression.